TheStreet Ratings

10 Best Biotech Stocks for 2016 - Top Stocks - TheStreet Ratings

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology

Source: TheStreet Ratings

Best Investments for

Biotechnology News

AstraZeneca's Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.
10/26/16 7:40AM
Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.
10/25/16 5:03PM
The market is acting like resunab is a real drug, which is why my investor source is short Corbus.
10/25/16 8:44AM
Global Blood wants to start screening sickle cell disease patients for the phase III study in December with the hope of having top-line results in the first half of 2019.
10/24/16 4:05PM
Third time was the charm for Alkermes' experimental antidepressant ALKS 5461.
10/20/16 4:06PM
Gilead is under enormous pressure from investors to acquire companies or develop new drugs from its pipeline.
10/20/16 12:24PM
Puma CEO Alan Auerbach wanted the cash desperately, regardless of Puma's stock price. Get the deal done, even if you have to sell it to the shorts.
10/20/16 8:40AM
Celgene is not some dinky micro-cap biotech lacking the resources or knowledge to conduct a rigorous clinical trial, so omitting a placebo arm from the GED-0301 study is inexcusable.
10/19/16 7:28AM
Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.
10/17/16 11:31AM
On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.
10/17/16 8:32AM
Investors had reduced expectations for Celgene's experimental pill for Crohn's disease, which makes the new clinical data released Sunday night look all right, although doubts will persist.
10/17/16 6:46AM
The biotech firm's stock sold off sharply during Friday's trading session -- one day after announcing improvements to its gene therapy for rare blood diseases.
10/14/16 5:27PM
Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.
10/13/16 11:39AM
Tesaro is soaring, but the company is overvalued if regulators decide to grant marketing clearance for niraparib only in a smaller, more restricted population of ovarian cancer patients.
10/10/16 1:22PM
Six of nine breast cancer patients treated with an experimental gene therapy from Ziopharm Oncology ZIOP experienced a potentially dangerous immune system-related toxicity known as cytokine release syndrome.
10/10/16 8:58AM